Alberto Bardelli

Dr. Alberto Bardelli

orcid

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2014 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
CBChetan Bettegowda
Chetan Bettegowda
MSMark Sausen
Mark Sausen
RLRebecca J. Leary
Rebecca J. Leary
IKIsaac Kinde
Isaac Kinde
YWYuxuan Wang
Yuxuan Wang
LDLuis A. Diaz
Luis A. Diaz
The development of noninvasive methods to detect and monitor tumors continues to be a major challenge in oncology. We used digital polymerase chain reaction–based technologies to evaluate the ability of circulating tumor DNA (ctDNA) to detect tumors in 640 patients with various cancer types. We found that ctDNA was detectable in >75% of patients with advanced pancreatic, ovarian, colorectal, bladder, gastroesophageal, breast, melanoma, hepatocellular, and head and neck cancers, but in less than 50% of primary brain, renal, prostate, or thyroid cancers. In patients with localized tumors, ctDNA was detected in 73, 57, 48, and 50% of patients with colorectal cancer, gastroesophageal cancer, pancreatic cancer, and breast adenocarcinoma, respectively. ctDNA was often present in patients without detectable circulating tumor cells, suggesting that these two biomarkers are distinct entities. In a separate panel of 206 patients with metastatic colorectal cancers, we showed that the sensitivity of ctDNA for detection of clinically relevant KRAS gene mutations was 87.2% and its specificity was 99.2%. Finally, we assessed whether ctDNA could provide clues into the mechanisms underlying resistance to epidermal growth factor receptor blockade in 24 patients who objectively responded to therapy but subsequently relapsed. Twenty-three (96%) of these patients developed one or more mutations in genes involved in the mitogen-activated protein kinase pathway. Together, these data suggest that ctDNA is a broadly applicable, sensitive, and specific biomarker that can be used for a variety of clinical and research purposes in patients with multiple different types of cancer.

23 April 2004 in Science
Verified
Journal Article
Closed access
PDF file
YSYardena Samuels
Yardena Samuels
ZWZhenghe Wang
Zhenghe Wang
ABAlberto Bardelli
Alberto Bardelli
NSNatalie Silliman
Natalie Silliman
JPJanine Ptak
Janine Ptak
VVVictor E. Velculescu
Victor E. Velculescu

5 July 2016 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
ECE. Van Cutsem
E. Van Cutsem
Andres CervantesAndres Cervantes
Andres Cervantes
RAR. Adam
R. Adam
ASA. Sobrero
A. Sobrero
JKJ. H. Van Krieken
J. H. Van Krieken
DAD. Arnold
D. Arnold
Colorectal cancer (CRC) is one of the most common malignancies in Western countries. Over the last 20 years, and the last decade in particular, the clinical outcome for patients with metastatic CRC (mCRC) has improved greatly due not only to an increase in the number of patients being referred for and undergoing surgical resection of their localised metastatic disease but also to a more strategic approach to the delivery of systemic therapy and an expansion in the use of ablative techniques. This reflects the increase in the number of patients that are being managed within a multidisciplinary team environment and specialist cancer centres, and the emergence over the same time period not only of improved imaging techniques but also prognostic and predictive molecular markers. Treatment decisions for patients with mCRC must be evidence-based. Thus, these ESMO consensus guidelines have been developed based on the current available evidence to provide a series of evidence-based recommendations to assist in the treatment and management of patients with mCRC in this rapidly evolving treatment setting.

20 February 2014 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
LDLuis A. Diaz
Luis A. Diaz
ABAlberto Bardelli
Alberto Bardelli
Genotyping tumor tissue in search of somatic genetic alterations for actionable information has become routine practice in clinical oncology. Although these sequence alterations are highly informative, sampling tumor tissue has significant inherent limitations; tumor tissue is a single snapshot in time, is subject to selection bias resulting from tumor heterogeneity, and can be difficult to obtain. Cell-free fragments of DNA are shed into the bloodstream by cells undergoing apoptosis or necrosis, and the load of circulating cell-free DNA (cfDNA) correlates with tumor staging and prognosis. Moreover, recent advances in the sensitivity and accuracy of DNA analysis have allowed for genotyping of cfDNA for somatic genomic alterations found in tumors. The ability to detect and quantify tumor mutations has proven effective in tracking tumor dynamics in real time as well as serving as a liquid biopsy that can be used for a variety of clinical and investigational applications not previously possible.

26 January 2012 in Nature
Verified
Journal Article
Closed access
PDF file
APAnirudh Prahallad
Anirudh Prahallad
CSChong Sun
Chong Sun
SHSidong Huang
Sidong Huang
Federica Di NicolantionioFederica Di Nicolantionio
Federica Di Nicolantionio
RSRamon Salazar
Ramon Salazar
RBRené Bernards
René Bernards

1 August 2010 in The Lancet Oncology
Verified
Journal Article
Closed access
WRWendy De Roock
Wendy De Roock
BCBart Claes
Bart Claes
DBDavid Bernasconi
David Bernasconi
JSJef De Schutter
Jef De Schutter
BBBart Biesmans
Bart Biesmans
STSabine Tejpar
Sabine Tejpar